Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (GB:0LC7)
LSE:0LC7
RESEARCH TOOLSreports
Holding GB:0LC7?
Track your performance easily
0LC7 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.44 - $8.10
Previous Close$1.95
Volume7.11K
Average Volume (3M)23.03K
Market Cap
$52.28M
Enterprise Value$33.98M
Total Cash (Recent Filing)$78.96M
Total Debt (Recent Filing)$60.66M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 12, 2024EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,809,764
10 Day Avg. Volume9,919
30 Day Avg. Volume23,033
Standard Deviation0.37
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-7.70
Price to Sales (P/S)12.60
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.19
Enterprise Value/Gross Profit3.42
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$5.00Price Target Upside156.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Syros Pharmaceuticals News
PremiumCompany Announcements
Syros Pharmaceuticals Reports SELECT-AML-1 Trial Outcomes
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 SELECT-MDS-1 study successfully passed a predetermined interim futility analysis regarding the complete response rate, conducted by an Independent Data Monitoring Committee.
Financial PerformanceFinancial results were largely consistent with consensus estimates, and Syros ended the quarter with $79MM in cash and reiterated guidance for runway into 3Q25.
Regulatory ApprovalsThe FDA recently granted Fast Track Designation to tamibarotene in combination with venetoclax and azacitidine.
Bears Say
Clinical Trial DiscontinuationThe discontinuation of enrollment in the SELECT-AML-1 Phase 2 study challenges the thesis and overall investor narrative regarding the program.
Financial Valuation ImpactThe discontinuation of enrollment in SELECT-AML-1 led to the removal of all associated revenue from the valuation.
Trial Outcome And AnalysisSyros announced negative interim futility results from the SELECT-AML-1 trial for tamibarotene in newly diagnosed RARA positive, unfit AML patients.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.18% Insiders
4.69% Mutual Funds
0.15% Other Institutional Investors
89.37% Public Companies and
Individual Investors
0LC7 FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest share price was $1.44 and its highest was $8.10 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Currently, no data Available
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is Nov 12, 2024 which is in 24 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Jul 31, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.767 by $0.177.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -$0.68.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,809,765 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.767. Following the earnings report the stock price went down -1.221%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Among the largest hedge funds holding Syros Pharmaceuticals’s share is Flagship Pioneering Inc.. It holds Syros Pharmaceuticals’s shares valued at 7M.
---
Syros Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (156.02% Upside)
$5.00 (156.02% Upside)
Blogger Sentiment
Bullish
GB:0LC7 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $320.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.98%
12-Months-Change
Fundamentals
Return on Equity
-393.39%
Trailing 12-Months
Asset Growth
-41.03%
Trailing 12-Months
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
0LC7 Earnings Call
Q2 2024
0:00 / 0:00
---
0LC7 Stock 12 Month Forecast
Average Price Target
$5.00
▲(156.02% Upside)
Technical Analysis
Mersana Therapeutics
―
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering 0LC7
1 Year
1 Year Success Rate
6/25 ratings generated profit
1 Year Average Return
-35.62%
reiterated a buy rating 2 months ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 24.00% of your transactions generating a profit, with an average return of -35.62% per trade.
---